Clobetasol Propionate Patent Expiration
Clobetasol Propionate is Used for treating skin diseases using a corticosteroid-containing pharmaceutical composition. It was first introduced by Fougera Pharmaceuticals Inc
Clobetasol Propionate Patents
Given below is the list of patents protecting Clobetasol Propionate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Byqlovi | US10588913 | Aqueous suspension agent containing glucocorticosteroid nanoparticles | May 09, 2036 | Formosa |
| Byqlovi | US11376262 | Method of treating an inflammatory or infectious disease | May 09, 2036 | Formosa |
| Impoyz | US9855334 | Topical compositions comprising a corticosteroid | Mar 11, 2035 | Primus Pharms |
| Impoyz | US10064875 | Topical formulations comprising a steroid | Aug 31, 2030 | Primus Pharms |
| Impoyz | US10588914 | Topical formulations comprising a steroid | Aug 31, 2030 | Primus Pharms |
| Impoyz | US9956231 | Topical formulations comprising a steroid | Aug 31, 2030 | Primus Pharms |
| Olux E | US8460641 | Microemulsion process and composition | Nov 05, 2028 | Pharmobedient |
| Olux E | US8962000 | Microemulsion and sub-micron emulsion process and compositions | Aug 31, 2025 | Pharmobedient |
| Clobex | US7700081 | Foaming compositions for hair care |
Jan 03, 2022
(Expired) | Galderma Labs |
| Olux E | US6730288 | Mousse composition |
Sep 08, 2019
(Expired) | Pharmobedient |
| Olux E | US7029659 | Mousse composition |
Sep 08, 2019
(Expired) | Pharmobedient |
| Clobex | US7316810 | Foaming composition for washing and treating hair and/or scalp based on an active principle |
Jun 17, 2019
(Expired) | Galderma Labs |
| Clobex | US8066975 | Foaming composition for washing and treating hair and/or scalp based on an active principle |
Jun 17, 2019
(Expired) | Galderma Labs |
| Clobex | US8066976 | Foaming compositions for hair care |
Jun 17, 2019
(Expired) | Galderma Labs |
| Clobex | US5990100 | Composition and method for treatment of psoriasis |
Mar 24, 2018
(Expired) | Galderma Labs Lp |
| Clobex | US5972920 | Formulation containing a carrier, active ingredient, and surfactant for treating skin disorders |
Feb 12, 2018
(Expired) | Galderma Labs Lp |
| Clobex | US6106848 | Topically applicable O/W emulsions having high glycol content and at least one biologically active agent |
Sep 22, 2017
(Expired) | Galderma Labs Lp |
| Olux | US6126920 | Method of treating a skin disease with a corticosteroid-containing pharmaceutical composition |
Mar 01, 2016
(Expired) | Norvium Bioscience |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Clobetasol Propionate's patents.
Latest Legal Activities on Clobetasol Propionate's Patents
Given below is the list recent legal activities going on the following patents of Clobetasol Propionate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 17 Mar, 2023 | US10588913 |
| Patent Issue Date Used in PTA Calculation Critical
| 05 Jul, 2022 | US11376262 |
| Recordation of Patent Grant Mailed Critical
| 05 Jul, 2022 | US11376262 |
| Email Notification Critical
| 16 Jun, 2022 | US11376262 |
| Issue Notification Mailed Critical
| 15 Jun, 2022 | US11376262 |
| Application Is Considered Ready for Issue Critical
| 25 May, 2022 | US11376262 |
| Dispatch to FDC | 25 May, 2022 | US11376262 |
| Issue Fee Payment Received Critical
| 20 May, 2022 | US11376262 |
| Issue Fee Payment Verified Critical
| 08 May, 2022 | US11376262 |
| Mail Response to 312 Amendment (PTO-271) Critical
| 08 Apr, 2022 | US11376262 |
Clobetasol Propionate's Family Patents
